Risk of second primary cancer in patients with B-cell non-Hodgkin lymphoma receiving rituximab-containing chemotherapy: a nationwide population-based study.
OBJECTIVE
This study aimed to evaluate the risk of second primary cancer (SPC) in patients receiving rituximab-containing chemotherapy.


METHODS
A nationwide, population-based study was conducted using the National Health Insurance Database of Taiwan. Propensity score matching was performed to correct sample selection bias and logistic regression analysis was used to calculate odds ratios.


RESULTS
Patients receiving rituximab-containing chemotherapy or conventional chemotherapy were enrolled. After adjustment by propensity score matching, there were 1,607 patients in each group. SPC was noted in 11 patients (0.68%) with rituximab-containing chemotherapy and in 19 patients (1.18%) with conventional chemotherapy (p=0.142). There was no significant difference in the age distribution at onset of SPC (p=0.327). Multivariate logistic regression analysis revealed rituximab-containing chemotherapy was not associated with risk of SPC (odds ratio (OR)=0.58; 95% confidence interval (CI)=0.28-1.23; p=0.157).


CONCLUSIONS
Incorporation of rituximab into conventional anti-lymphoma chemotherapy did not increase the risk of SPC in patients with B-cell non-Hodgkin lymphoma (NHL).
Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C. Division of Hematology & Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
Shih-Feng
SF
Cho
Division of Hematology and Oncology, E-Da Hospital, Kaohsiung, Taiwan, R.O.C. School of Medicine, I-Shou University, Kaohsiung, Taiwan, R.O.C.
Wan-Hsuan
WH
Wu
School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
Yi-Hsin
YH
Yang
Division of Hematology and Oncology, E-Da Hospital, Kaohsiung, Taiwan, R.O.C. School of Medicine, I-Shou University, Kaohsiung, Taiwan, R.O.C. ccschang@gmail.com.
Chao-Sung
CS
Chang
D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D016015:Logistic Models; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000209:etiology*; D012306:Risk; D000069283:Rituximab
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab
Non-Hodgkin lymphoma; rituximab; second primary cancer